<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIHYDROERGOTAMINE MESYLATE</span><br/>(dye-hye-droe-er-got'a-meen)<br/><span class="topboxtradename">D.H.E. 45, </span><span class="topboxtradename">Migranal<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist</span>; <span class="classification">ergot alkaloid</span><br/><b>Prototype: </b>Ergotamine<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg/mL nasal spray; 1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Alpha-adrenergic blocking agent and dihydrogenated ergot alkaloid with direct constricting effect on smooth muscle of peripheral
         and cranial blood vessels. Maintains elevated levels of circulating norepinephrine (vasoconstrictor action) by inhibiting
         its reuptake. Vasoconstrictor action is more prominent on capacitance vessels (veins, venules) than on resistance vessels
         (arteries, arterioles).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces rate of serotonin-induced platelet aggregation. Has somewhat weaker vasoconstrictor action than ergotamine but greater
         adrenergic blocking activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To prevent or abort vascular headache (e.g., migraine or histaminic cephalalgia) when rapid control is desired or other routes
         are not feasible. With low-dose heparin therapy to prevent postoperative deep-vein thrombosis and pulmonary embolism.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To treat postural hypotension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to ergot preparations; peripheral vascular disease, coronary heart disease, hypertension; peptic
         ulcer; impaired hepatic or renal function; sepsis. Safe use during pregnancy (category X), lactation, or in children is not
         established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Migraine Headache</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM/SC</span> 1 mg, may be repeated at 1 h intervals to a total of 3 mg IM or 2 mg IV/SC (max: 6 mg/wk) <span class="rdroute">Intranasal</span> 1 spray (0.5 mg) in each nostril, may repeat with additional spray in 15 min if no relief (max: 4 sprays per attack); wait
               68 h before treating another attack (max: 8 sprays per 24 h, 24 sprays/wk)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intranasal</span><br/><ul>
<li>Give at first warning of migraine headache.</li>
<li>Optimum results: Titrate the doses required to bring relief for several headaches to determine the minimal effective dose.
            Use the established dose for subsequent attacks.
         </li>
</ul><span class="adminroutetype">Intramuscular/Subcutaneous</span><br/><ul>
<li>Withdraw IM or SC dose directly from ampule. Do not dilute.</li>
<li>
            				Note: Onset of action is about 20 min; when rapid relief is required, the IV route is prescribed.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 1 mg/60 sec.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
<li>Protect ampoules from heat and light; do not freeze.</li>
<li>Discard ampoule if solution appears discolored.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Vasospasm: coldness, numbness and tingling in fingers and toes, muscle pains and weakness of legs, precordial distress and
      pain, transient tachycardia or bradycardia, hypertension (large doses). <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting.</span>
<span class="typehead">Body as a Whole:</span> Dizziness, dysphoria, <span class="speceff-common">localized edema and itching;</span> ergotism (excessive doses). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">beta blockers</span>, <b>erythromycin</b> increase peripheral vasoconstriction with risk of ischemia; increased <b>ergotamine</b> toxicity with drugs that inhibit CYP3A4 (e.g.,<span class="classification">protease inhibitors,</span>
<b>amprenavir,</b>
<b>ritonavir,</b>
<b>nelfinavir,</b>
<b>indinavir,</b>
<b>saquinavir</b>), <span class="classification">macrolide antibiotics</span>
<b>(erythromycin,</b>
<b>azithromycin,</b>
<b>clarithromycin),</b>
<span class="classification">azole antifungals</span>
<b>(ketoconazole,</b>
<b>itraconazole,</b>
<b>fluconazole,</b>
<b>clotrimazole),</b>
<b>nefazodone,</b>
<b>fluoxetine,</b>
<b>fluvoxamine.</b>
<span class="typehead">Food:</span>
<b>Grapefruit juice</b> may increase toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 1530 min IM; Duration: 34 h. <span class="typehead">Distribution:</span> Probably distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine; some excreted in feces. <span class="typehead">Half-Life:</span> 2132 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status, especially when large doses are given.</li>
<li>Monitor for and report numbness and tingling of fingers and toes, extremity weakness, muscle pain, or intermittent claudication.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take at first warning of migraine headache.</li>
<li>Lie down in a quiet, darkened room for several hours after drug administration for best results.</li>
<li>Report immediately if any of the following S&amp;S develop: Chest pain, nausea, vomiting, change in heartbeat, numbness, tingling,
            pain or weakness of extremities, edema, or itching.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>